

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) Method of analysis of the tumor aggressivity of cancerous cells consisting of the measurement of the quantity of polymerized actin in the steady state in a lysate of the said cells

wherein the measurement of the quantity of actin in the steady state is carried out by static fluorescence polarization in the presence of actin monomers bound to a fluorochrome, the monomers being incorporated into the actin filaments (actin F) formed during the endogenous actin polymerization of the lysate.

2. (Previously Presented) Method according to claim 1, wherein the measurement carried out on the lysate is compared to one or more reference values of the quantity of polymerized actin in the steady state.

3. (Previously Presented) Method according to claim 1, wherein the quantity of polymerized actin corresponds to the sum of all the F-form actin.

4. (Cancelled)

5. (Currently Amended) Method according to claim 1 [[4]], wherein the actin monomers bound to a fluorochrome are added to the cellular lysate in a proportion ranging between $1/80^{\text{th}}$ and $1/1600^{\text{th}}$ in relation to the quantity of endogenous actin.

6. (Currently Amended) Method according to claim 1, including the steps of:

- ~~the lysis of~~ lysing cancerous cells in non-denaturing conditions for the proteins,

and the ~~elimination of~~ eliminating cellular debris,

- ~~the determination of~~ determining the total amount ~~total dosage~~ of proteins in the lysate,
- ~~the addition of~~ adding actin monomers bound to a fluorochrome,
- ~~the addition of~~ adding one or more substances ~~necessary for the~~ to activate endogenous actin polymerization and ~~the protection of~~ protect the lysate proteins, wherein said substances are selected from the group consisting of subunits of the Arp2/3 complex and the Ena/VASP family of proteins, and
- ~~the measurement of~~ measuring the quantity of polymerized actin in the steady state in the lysate.

7. (Currently Amended) Method of identification of molecules likely to present an anti-cancer activity, comprising implementing a method according to one of claims 1-3 and 5-6 ~~4 to 6~~ in the presence of an ~~appropriate~~ quantity of ~~[[the]]~~ said molecule, and determining the capacity of ~~[[the]]~~ said ~~substance~~ molecule to restore a quantity of polymerized actin in the steady state corresponding to that of non-aggressive cells is determined.

8. (Currently Amended) ~~Application of~~ A method of evaluating cancer cells to determine their invasiveness, comprising carrying out the method according to one of claims 1-3 and 5-6 ~~1 to 6 to the evaluation of the invasive character of the said cells.~~

9. (Currently Amended) ~~Application of~~ A method of evaluating cancer cells to determine their oncogenicity, comprising carrying out the method according to one of claims 1-3 and 5-6 ~~1 to 6 to the evaluation of the oncogenicity of the said cells.~~

10. (Currently Amended) ~~Application of~~ A method of evaluating cancer cells to determine their sensitivity to an anti-cancer treatment, comprising carrying out the method according to one of claims 1-3 and 5-6 ~~1 to 6 to the prediction of the sensitivity of the said cells to an anti-cancer treatment.~~

11. (Currently Amended) ~~Application~~ The method according to claim 10, wherein the said anti-cancer treatment consists of radiotherapy or chemotherapy.

12. (Currently Amended) A kit for the implementation of a method according to one of claims 1-3 and 5-6 ~~1 to 6~~, including:

- a cell re-suspension medium for the cell lysis,
- ~~[[the]]~~ one or more substances ~~necessary for the~~ to activate endogenous actin polymerization and ~~the protection of~~ protect the lysate proteins, wherein said substances are selected from the group consisting of subunits of the Arp2/3 complex and the Ena/VASP family of proteins,
- a solution of actin monomers bound to a fluorochrome,
- an actin polymerization ~~tampen~~ solution, and
- a general actin ~~tampen~~ solution
- ~~possibly the extracts of aggressive and non-aggressive reference cells.~~

13. (New) The kit according to claim 12, wherein the kit further includes extracts of aggressive and non-aggressive reference cells.